Background
Infection is the most common presentation among hospitalized patients of intensive care unit (ICU), and in many instances, is a determining factor for patient outcomes [
1,
2]. Healthcare associated infections (HCAIs), in particular, are the major risks associated with critically ill patients of ICU, due to the reduced host defenses, frequent use of invasive medical devices, administration of multiple drugs, cross transmission of pathogens among patients and staffs, and inadequate infection control procedures [
3,
4]. Hence, intensive care units (ICUs) are now often recognised as the epicenter of infections in the hospital [
5]. Pneumonia, surgical-site infections, catheter-related bloodstream infections and urinary tract infections are currently the most common cause of death in ICU due to healthcare associated infections [
6]. According to a large surveillance study, more than 70% of critically ill patients receive an antimicrobial drug during their ICU stay either for prophylaxis or for therapy [
1]. Nevertheless, in the recent years, therapeutic drugs are being progressively ineffective against bacterial infections, threatning the success of routine treatment [
7]. The major consequences of this problem are increased patient morbidity, mortality, health care related expenses and treatment failure [
8,
9].
β-lactam antibiotics are the major bulk of prescribed antibiotics in ICUs across the globe because of their efficacy, broad spectra and low toxicity [
10]. However, irrational use of these antibiotics has resulted in the development and spread of drug resistant bacterial pathogens especially in the developing countries [
11]. Of the particular concern, increased occurrence of Gram negative bacteria, including multidrug resistant nonfermenters (
Acinetobacter baumannii and Pseudomonas species) and Enterobacteriaceae producing extended-spectrum beta-lactamase(ESBL) and carbapenemases in severe healthcare-associated infections has evolved as a significant clinical threat for medical fraternity in the recent decades [
12,
13]. The broad substrate profile of these enzymes may affect entire beta lactam agents, and also the organisms with these enzymes are additionally found resistant to aminoglycosides and fluoroquinolones, further compromising the therapeutic choices for severe infections in ICU [
14,
15].
In Nepal, international guidelines on initial antibiotic selection are generally applied in ICUs and empiric choices are made for serious ICU related infections. Thorough knowledge of epidemiology, spectrum and nature of infections along with susceptibilities of causative organisms are extremely valuable for empirical treatment of severe infections in intensive care hospital settings. Therefore, it would be an effective measure for policy formulation of judicious antimicrobial therapy for critically ill patients in the intensive care units of various hospitals in our country. In this perspective, we aimed to determine the incidence of multidrug resistant bacteria, their susceptibilities and common mechanisms of drug resistance involved in healthcare associated infections in the critically ill patients of an intensive care unit at a tertiary care teaching hospital in Kathmandu, Nepal.
Discussion
Increased consumption of antimicrobial regimens, higher prevalence and dissemination of drug resistance among nosocomial pathogens and poor infection control strategies for prevention of healthcare associated infections are the rising problems in Nepalese hospitals [
23]. The problem is several-folds high in the intensive care units where collection of severely ill patients from all over the hospital units with varieties of pathological profile and etiological agents exists. Therefore, identification of the underlying pattern of drug resistance among microorganisms in every hospital is the key to success in the appropriate treatment of patients. This issue is of interest especially in Nepalese ICUs where the highest prevalence of patients on antibiotic treatment is frequently reported.
The rate of healthcare associated infections varies globally and higher rates have been reported from developing countries [
24]. Moreover, the type of hospital setting (ward or intensive care unit), patient population and the precise definition and surveillance techniques used to identify the healthcare associated infections are responsible for variable incidences [
25]. Healthcare associated infections are frequent in our study as previously described by Sah et al. from same hospital [
26], although they have included the patients from all sections of hospital, providing heterogeneity of the cases. However, extremely high incidences have been documented in recent reports from India (11.9-17.7%) [
27,
28]. In the well known EPIC II study by Vincent et al., 51% of the patients in ICU were found infected [
1]. Another multicentre cohort study yielded the rate of infections in ICU patients around the globe to be ranging from 2.3 to 49.3% [
29]. However, the higher rates in multicentre studies are due to the heterogeneous patients, study parameters, voluntary participation and reporting, as well as the variation in surveillance techniques [
30].
We observed hospital acquired pneumonia (53%) to be the most common healthcare associated infection in this study, followed by bloodstream infections (18.8%), surgical site infections (15.4%) and urinary tract infections (12.8%) which are comparable to the findings of large EPIC II study [
1]. Similar findings were also been reported from epidemiological study of infections in ICU population by Cosic et al. from Brazil [
31] and Dasgupta et al. from India [
28]. However, in a recent report, Mythri and Kashinath pointed UTI as the most common infection, followed by pneumonia and surgical site infections [
27]. The site distribution of infections in various studies might be attributable to the type of ICUs and patient population. Our report broadly corroborates to the findings of earlier studies mentioned above.
Non fermentative Gram negative bacteria including enterobacteriaceae are increasingly reported as the cause of healthcare associated infections worldwide [
32].
Acinetobacter species, major pathogenic organism in health-care-associated infections, was found to be the most common organisms in our ICU. Majority of the infections associated with
Acinetobacter were pneumonia and surgical site infections. Similar spectrum of bacterial pathogens in healthcare associated infections in ICU has been documented by other studies too [
26,
33]. However,
Burkholderia cepacia was the most common bacteria isolated from bloodstream infections in our ICU. Increased use of pharmaceutical derivatives and accumulation of sicker patients with variable infections might be the reason for our shifting etiology.
Antimicrobial resistance is a recognized problem in South Asian region with high levels of resistance among Gram negative organisms reported frequently [
34]. It is well known fact that resistance is due to extreme antimicrobial consumption [
11], and overuse of antibiotics can be surmised as one of the factors contributing to the high rates of antimicrobial resistance in Nepal. In this study, many microorganisms found as resistant to different antimicrobial agents and in some cases to nearly all agents representing an alarming scenario in our intensive care setting. Nearly 96% of the Gram negative bacterial isolates causing nosocomial infections were found multidrug resistant, which is highest ever rate of MDR bacteria reported from our country. Earlier reports from Nepal have reported upto 95% of the nosocomial isolates as drug resistant [
35,
36]. Further in this study, not only the isolates were multidrug resistant, a significant proportion (43.3%) of our isolates was extensively drug resistant (XDR). The high level of drug resistance in Gram negative isolates have been described as a result of the production of different 훽-lactamases, multiple efflux pumps, decreased drug uptake, and other drug modifying enzymes [
37].
Gram negative non-fermenters were more resistant to antimicrobial drugs in this study.
Acinetobacter isolates were found highly resistant to carbapenem (86.4%), aminoglycosides (93%) and cephalosporins (100%) groups of antibiotics which is nearly twofold high than that reported by Mishra et al. from same hospital (nearly 89% resistance in cephalosporins and 50% in carbapenem) [
35]. However, the resistance rate of Gram negative nonfermenters in our study is comparable to the study of Xia et al. from China [
38] and Fatima et al. from Pakistan [
39]. Moreover, a SENTRY study also reported that Gram negative bacterial resistance to imipenem changed from 34.5% in 2006 to 59.8% in 2009 across the world [
40]. In addition to this, the increasing emergence of highly aminoglycosides-resistant strains is also cause of major concern. Our result on amikacin resistance (up to 85%) is higher than that (54%) of previous study from same hospital [
35]. Although none of the
Acinetobacter strains in our study was tigecycline and colistin resistant, it has been indicated as an emerging therapeutic problem which may severely compromise the treatment of MDR
Acinetobacter spp. infections [
41]. This high prevalence of multi drug resistance in
Acinetobacter spp. may be due to high chance of acquisition of resistance gene and their ability to persist and multiply in hospital environment [
42]. On the other hand,
Pseudomonas aeruginosa and
Burkholderia cepacia are intrinsically resistant to several antibiotics because of the low permeability of their outer-membrane, the constitutive expression of various efflux pumps, and the production of antibiotic-inactivating enzymes (e.g., cephalosporinases) [
43].
Enterobacteriaceae, including
Escherichia coli, Klebsiella spp. and
Citrobacter spp. were also found resistant to multiple antibiotics. Resistance of enterobacterial strains towards cephalosporins (100%), fluoroquinolones (86.4 to 100%), aminoglycosides (45.1 to 100%) and carbapenems (19.3 to 48.6%) was considerably high when compared to the reported rates from previous studies [
36,
44]. However, tigecycline and polymixins showed excellent effect against MDR Gram-negative enterobacterial isolates. High antibiotic resistance rate against commonly used antibiotics is a disadvantage for health care system in countries like Nepal as it can greatly affect patient management especially in critical care units.
Beta lactamases are the hydrolytic enzymes thwarting the functional part of
β-lactam antibiotics used for the treatment of most bacterial infections. The menacing state of resistance in Gram negative isolates towards the cephalosporins, carbapenems and other antibiotics could be attributed to ESBL, AmpC β-lactamase, carbapenamase producers and some other relevant underlying mechanisms [
45]. In this study, the rates of beta lactamase production, including ESBL, AmpC, MBL, and KPC were alarmingly high.
Escherichia coli, Klebsiella spp
.,
Citrobacter spp.,
Pseudomonas spp. and
Burkholderia spp. were major ESBL producers. Previously, Shrestha et al. in 2011 have also reported 28.57% of
Escherichia coli, 8.33% of
Klebsiella spp. and 2.38% of
Pseudomonas aeruginosa were ESBL producers [
46]. However, in an Indian study, the rate of ESBL production among nosocomial isolates was 50% in
Escherichia coli and 67% in
Klebsiella pneumoniae respectively [
41]. Variations in ESBL rates may be ascribed to antibiotic prescribing habits and endemicity of pathogens harboring the genes for ESBL production. Furthermore, we detect 27.5% AmpC producing isolates, including
Acinetobacter spp. (42.3%) followed by
Escherichia coli (38.7%) and
Klebsiella pneumoniae (32.4%) which is comparative to the previous reports of Baral et al. [
47] and Khanal et al. [
36] from nearby hospital. However, in an Indian study lower rate (14.2%) of AmpC producing isolates were documented [
48].
High resistance of carbapenems in our study has been supported by the detection of carbapenemase enzyme in the bacterial isolates. Major bacterial isolates producing MBL were
Acinetobacter spp.,
Pseudomonas spp.,
Klebsiella spp. and
Burkholderia spp. Although, till date, there is no single article regarding detection of KPC from Nepal, this study attempted to find out the KPC producing bacterial isolates in ICU population. In Nepal, carbapenamase producing bacteria are poorly reported. Mishra et al. documented the rate of MBL producers to be 1.3% including
Acinetobacter (4.3%),
Pseudomonas (3.3%) [
49], but in a study by Shrestha et al. the rate of MBL was 17.43% among nosocomial isolates including
Acinetobacter (47.22%),
Pseudomonas (2.38%) and of
Klebsiella spp. (4.17%) [
46]. The emergence of carbapenamase in Gram negative bacilli is becoming a therapeutic challenge as these enzymes possess high hydrolytic activity that leads to degradation of higher generation cephalosporins and carbapenems. Furthermore, these plasmid mediated genes have the ability spread rapidly to other species of Gram negative bacilli [
50]. Therefore rapid detection of these resistance determinants is necessary to modify therapy and to initiate effective infection control to prevent their dissemination.
Limitations
We could not evaluate the risk factors and outcomes of nosocomial infections associated with drug resistant bacteria. Due to the unavailability of sufficient data from the patients without healthcare associated infections, statistical comparison between the patients with and without healthcare associated infections could not been made. Further, it was limited to a mixed adult ICU of a teaching hospital leaving other surgical and pediatric ICU patients. Furthermore, molecular characterization of the resistant phenotypes and their epidemiology would be more significant in public health perspective.